In clinic,
metastasis is still the main reason for death for
cancer patients. Therefore, it is necessary to track
cancer metastases accurately, kill
cancer cells effectively, and then improve the prognosis of patients with advanced
cancer. Therefore, we designed a
liposome-based pretargeted system modified with
single-stranded DNA and targeting
peptide injected in sequence and then assembled in vivo for multimodality imaging-guided pretargeted synergistic
therapy of metastatic
breast cancer. The pretargeted system is composed of the first
liposome, loaded with near-infrared fluorescence imaging (NIR-II) probe downconversion nanoprobes (
DCNP) and magnetic resonance imaging (MRI)
contrast agent SPIO (L1/C-Lipo/DS), for primary/metastatic
tumor MRI/NIR-II dual-modal imaging, and the second
liposome, loaded with
glucose oxidase (GOx) and
doxorubicin (DOX) (L2/C-Lipo/GD), as the therapeutic component. The
SPIO in L1/C-Lipo/DS accumulated in the
tumor tissue will provide a necessary
iron ion for the therapeutic
liposome (L2/C-Lipo/GD) to exert the pretargeted ferroptosis
therapy to
cancer cells. We demonstrate that the
DNA-mediated pretargeting strategy can realize the multimodality imaging-guided synergistically enhanced antitumor effect between the two
liposomes. This pretargeted and synergistic in vivo assembly nanomedicine strategy for diagnosis and treatment holds clinical translation potential for
cancer management.